**Industry Revenues:**
- **Biopharmaceuticals:** 70%
- **Vaccines:** 25%
- **Other Health Products:** 5%

**TOP 3 Markets:**
- **China:** 60%
- **Southeast Asia:** 20%
- **Latin America:** 10%

Chongqing Zhifei Biological Products Co., Ltd. generates the majority of its revenues from the biopharmaceutical industry, with vaccines also representing a significant portion. The Chinese market is the company's dominant market, followed by Southeast Asia and Latin America. These markets are crucial for the company's growth as they exhibit high demand for health products.

**Production Sites:** Chongqing, China

Chongqing Zhifei Biological Products Co., Ltd. mainly produces its products in Chongqing, China. The company is known for manufacturing vaccines and other biological products. Through strategic investments in its production facilities, Zhifei Biological has expanded its capacities to meet the increasing demand for its products.

Additionally, in recent years, the company has modernized its production processes to increase efficiency and improve product quality.

**Revenue Growth:** Estimated at 10-12% annually (2025, based on industry analysis)

**Research & Development:** Increase R&D spending by 15% (2025)

Chongqing Zhifei Biological Products Co., Ltd. pursues a growth strategy that is heavily focused on research and development. The company continuously invests in the development of new vaccines and biotechnological products to expand its product range and gain market share.

Another key element of the growth strategy is international expansion. Zhifei Biological aims to strengthen its presence in emerging markets, particularly in Asia and Africa, where the demand for vaccines is increasing.

Additionally, the company is pursuing strategic partnerships and alliances with other biopharmaceutical companies to gain access to new technologies and markets. These measures are intended to secure long-term growth and enhance competitiveness on a global scale.

**Raw Materials/Materials:** Adjuvants, Antigens, Excipients

**Main Import Countries:** USA, Germany, Switzerland

Chongqing Zhifei Biological Products Co., Ltd. is a leading company in vaccine production. For the manufacturing of their products, the company imports various raw materials and materials. These include especially adjuvants and antigens, which are essential for the effectiveness and stability of vaccines.

The USA, Germany, and Switzerland are significant suppliers of these materials. These countries are known for their advanced biotechnological and pharmaceutical industries, which provide high-quality raw materials for vaccine production. Collaborating with these countries enables Chongqing Zhifei to benefit from the latest scientific developments and technologies.

**Market share in China:** 20% (2024, estimated)
**Research and development ratio:** 8% of revenue (2024)
**Patents:** Over 200 active patents (2024)

Chongqing Zhifei Biological Products Co., Ltd. has a significant competitive advantage in the Chinese biotechnology and vaccine market. With an estimated market share of 20% in 2024, the company is one of the leading providers in China. This advantage is underscored by a strong focus on research and development, with approximately 8% of revenue being invested in this area.

The company has an extensive portfolio of over 200 active patents, highlighting its innovation capabilities and ability to develop new products. These patents not only secure the market position but also enable the development of new, innovative vaccines tailored to the specific needs of the market.

In addition, Chongqing Zhifei benefits from strategic partnerships and a strong local presence, facilitating access to key distribution channels and accelerating the market introduction of new products.

**Institutional Investor Share:** 45% (2025, estimated)
**Insider Buys/Sells:** No significant transactions reported (2025, estimated)

The institutional investor share of Chongqing Zhifei Biological Products Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors, suggesting confidence in the company's long-term performance.

In 2025, no significant insider buys or sells were reported. This could indicate that the management has confidence in the current valuation of the company and does not expect any significant changes in ownership structure.

**Market share of Chongqing Zhifei Biological Products Co., Ltd.:** 12% (2025, estimated)

**Top competitors and their market shares:**
1. **Sinovac Biotech Ltd.:** 18%
2. **CanSino Biologics Inc.:** 15%
3. **Beijing Tiantan Biological Products Corp., Ltd.:** 14%
4. **Chongqing Zhifei Biological Products Co., Ltd.:** 12%
5. **Hualan Biological Engineering Inc.:** 10%
6. **Shanghai Fosun Pharmaceutical Group Co., Ltd.:** 9%
7. **Walvax Biotechnology Co., Ltd.:** 8%
8. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.:** 7%
9. **Shenzhen Kangtai Biological Products Co., Ltd.:** 5%
10. **Zhejiang Hisun Pharmaceutical Co., Ltd.:** 2%

**Moat of Chongqing Zhifei Biological Products Co., Ltd.:**

Chongqing Zhifei Biological Products Co., Ltd. has a moderate moat, mainly based on its established product line and strong presence in the Chinese market. The company's advantage lies in its ability to quickly respond to local market needs and in close collaboration with research institutions to develop innovative vaccines.

Compared to its competitors, Sinovac Biotech has a stronger moat due to having a broader international presence and a diversified product range. CanSino Biologics and Beijing Tiantan Biological Products also have significant advantages through strategic partnerships and government support.

Overall, the moat of Chongqing Zhifei Biological Products Co., Ltd. is solid, but not as strong as some of its larger competitors, who have a greater international reach and diversified business models.

**Revenue Growth:** 18% (2024)
**Research and Development Expenses:** 12% of revenue (2024)
**Market Share in the Vaccine Sector:** 10% (2024, China)

Chongqing Zhifei Biological Products Co., Ltd. recorded a revenue growth of 18% in 2024, attributed to strong demand for their vaccines and successful market expansion. The company continues to heavily invest in research and development, with expenses amounting to 12% of revenue, indicating a strategic focus on innovation and product development.

The 10% market share in the Chinese vaccine sector demonstrates the company's strong position in a competitive market. These factors suggest that Zhifei Biological Products is well positioned to benefit from the growing demand for vaccines and biological products.

Overall, the stock could be an attractive investment for investors interested in long-term growth, particularly due to strategic investments in research and development and a strong market position.

**Dividend Yield:** 1.5% (2025, estimated)
**Dividend History:** Regular payouts since 2018

Chongqing Zhifei Biological Products Co., Ltd. has been regularly distributing dividends in recent years, with the dividend yield estimated to be around 1.5% in 2025. The company has maintained a consistent dividend policy since 2018, indicating a certain reliability in its payouts.

The stability of dividend payments is supported by the company's solid financial performance and strong market position. Therefore, investors can expect a continuation of dividend payments, provided that no significant market changes or internal challenges occur.